Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility

Wang,Weijia; Tu,Yi; Wang,Shanshan; Xu,Shan; Xu,Linlin; Xiong,Yifeng; Mei,Jinhong; Wang,Chunliang

doi:10.3892/mmr.2015.3805

Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility

Authors:
- Weijia Wang
- Yi Tu
- Shanshan Wang
- Shan Xu
- Linlin Xu
- Yifeng Xiong
- Jinhong Mei
- Chunliang Wang
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: May 21, 2015 https://doi.org/10.3892/mmr.2015.3805
Pages: 3575-3582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Meningiomas are common types of intracranial tumor. Invasive and malignant meningiomas present a significant therapeutic challenge due to high rates of recurrence and invasion. Understanding the molecular mechanism of invasion may assist in designing novel therapeutic approaches and improving patient survival rates. The HER‑2 gene has been demonstrated to be a useful predictor of tumor aggression, which promotes the survival and growth of cancer cells through the mitogen‑activated protein kinase and/or phosphatidylinositol 3‑kinase (PI3K)/AKT pathway. Until now, few studies have investigated the associateion between meningiomas and the expression of HER‑2, and the significance of HER‑2 in meningiomas remains to be elucidated. The present study aimed to investigate the effects of the HER‑2 gene on the biological behaviors of human malignant meningioma cells. The results demonstrated that downregulation of the expression of HER‑2 by small interfering RNA in human meningioma cells significantly inhibited cell motility and proliferation, led to cell cycle arrest at the G0/G1‑phase and increased early apoptosis. By contrast, the overexpression of HER‑2 group resulted in meningioma cell invasion, migration and proliferation being significantly enhanced, cell cycle was promoted at the G1/S‑phase and early apoptosis was decreased. Accordingly, the inhibition of HER‑2 also prevented the protein expression of PI3K and phosphorylated AKT. The results demonstrated that regulation of the HER‑2 gene can affect the proliferation, apoptosis, invasion and metastasis abilities of human meningioma cells in vitro. Furthermore, PI3K/AKT may contribute to the carcinogenesis and development of human meningiomas in combination with HER-2.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Chen L, Zou X, Wang Y, Mao Y and Zhou L: Central nervous system tumors: a single center pathology review of 34, 140 cases over 60 years. BMC Clin Pathol. 13:142013. View Article : Google Scholar
3	Mawrin C and Perry A: Pathological classification and molecular genetics of meningiomas. J Neurooncol. 99:379–391. 2010. View Article : Google Scholar : PubMed/NCBI
4	Andrae N, Kirches E, Hartig R, et al: Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer. 48:1831–1841. 2012. View Article : Google Scholar : PubMed/NCBI
5	Vranic A: Antigen expression on recurrent meningioma cells. Radiology and oncology. 44:107–112. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sahlberg KK, Hongisto V, Edgren H, et al: The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol. 7:392–401. 2013. View Article : Google Scholar
7	Liu X, Zhang Y, Ren W and Rao G: ErbB2 gene silencing and its effect on PTEN in SACC-83 salivary adenoid cystic carcinoma cells. Oncol Rep. 24:1291–1296. 2010.PubMed/NCBI
8	Way TD, Kao MC and Lin JK: Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 279:4479–4489. 2004. View Article : Google Scholar
9	Park HK, Kim IH, Kim J and Nam TJ: Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells. Int J Mol Med. 32:291–295. 2013.PubMed/NCBI
10	Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 92:1991–1998. 2000. View Article : Google Scholar : PubMed/NCBI
11	Pegram MD: Treating the HER2 pathway in early and advanced breast cancer. Hematol Oncol Clin North Am. 27:751–765. 2013. View Article : Google Scholar : PubMed/NCBI
12	Di Cosimo S, Arpino G and Generali D: Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer-moving beyond pathological complete response. Breast. 23:188–192. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ding H, Helguera G, Rodriguez JA, et al: Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release. 171:322–329. 2013. View Article : Google Scholar : PubMed/NCBI
14	Boku N: HER2-positive gastric cancer. Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar :
15	Qi W, Li X, Zhang Y, et al: Overexpression of Her-2 upregulates FoxM1 in gastric cancer. Int J Mol Med. 33:1531–1538. 2014.PubMed/NCBI
16	Jeung J, Patel R, Vila L, et al: Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. Arch Pathol Lab Med. 136:610–617. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chao WR, Lee MY, Lin WL, et al: HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. Hum Pathol. 45:810–816. 2014. View Article : Google Scholar : PubMed/NCBI
18	Waage IS, Vreim I and Torp SH: C-erbB2/HER2 in Human Gliomas, Medulloblastomas and Meningiomas: A Minireview. Int J Surg Pathol. 21:573–582. 2013. View Article : Google Scholar : PubMed/NCBI
19	Mahzouni P and Movahedipour M: An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade. Pathol Res Pract. 208:221–224. 2012. View Article : Google Scholar : PubMed/NCBI
20	Loussouarn D, Brunon J, Avet-Loiseau H, et al: Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol. 37:415–421. 2006. View Article : Google Scholar : PubMed/NCBI
21	Abdelzaher E, El-Gendi SM, Yehya A and Gowil AG: Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 25:707–713. 2011. View Article : Google Scholar
22	Fu J, Tian C, Xing M, et al: KU004 induces G1 cell cycle arrest in human breast cancer SKBR-3 cells by modulating PI3K/Akt pathway. Biomed Pharmacother. 68:625–630. 2014. View Article : Google Scholar : PubMed/NCBI
23	Khan S, Shukla S, Sinha S, Lakra AD, Bora HK and Meeran SM: Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Int J Biochem Cell Biol. 58:1–16. 2015. View Article : Google Scholar
24	Wang CL, Mei JH, Wang SS, et al: Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study. Zhonghua Bing Li Xue Za Zhi. 39:156–160. 2010.In Chinese. PubMed/NCBI
25	Lin VC, Chou CH, Lin YC, et al: Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. J Agr Food Chem. 58:4786–4793. 2010. View Article : Google Scholar
26	Kuo HP, Hsu SC, Ou CC, et al: Ganoderma tsugae extract inhibits growth of HER2-overexpressing cancer cells via modulation of HER2/PI3K/Akt signaling pathway. Evid Based Complement Alternat Med. 2013:2194722013. View Article : Google Scholar : PubMed/NCBI
27	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar
28	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
29	Bartholomeusz C and Gonzalez-Angulo AM: Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Tar. 16:121–130. 2012. View Article : Google Scholar
30	Steelman LS, Stadelman KM, Chappell WH, et al: Akt as a therapeutic target in cancer. Expert Opin Ther Targets. 12:1139–1165. 2008. View Article : Google Scholar : PubMed/NCBI
31	Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar : PubMed/NCBI
32	Lauring J, Park BH and Wolff AC: The Phosphoinositide-3-kina se-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 11:670–678. 2013.PubMed/NCBI
33	Briest F and Grabowski P: PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics. 4:336–365. 2014. View Article : Google Scholar : PubMed/NCBI
34	Jang YN and Baik EJ: JAK-STAT pathway and myogenic differentiation. Jak-Stat. 2:e232822013. View Article : Google Scholar : PubMed/NCBI
35	Kavitha K, Kowshik J, Kishore TK, et al: Astaxanthin inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta. 1830:4433–4444. 2013. View Article : Google Scholar : PubMed/NCBI